IV Sets in Massachusetts

Access Vascular, Inc manufactures vascular access devices designed to reduce complications associated with indwelling catheters. The company's primary product portfolio includes HydroPICC® (peripherally inserted central catheter) and HydroMID® (midline catheter) systems, both featuring the company's proprietary MIMIX® hydrophilic biomaterial technology. The MIMIX technology is engineered to mitigate thrombosis, a leading cause of catheter-related complications including occlusions and infections. Access Vascular's devices represent an alternative to standard polyurethane catheters and competing anti-thrombogenic/anti-microbial coated alternatives. The company emphasizes clinically demonstrated, statistically significant reductions in complications through in vitro, in vivo, and clinical data. Products are marketed toward acute care hospitals and clinical settings requiring central and midline vascular access. The company has published economic analyses suggesting potential savings of up to $1.8 million for large acute care hospitals through reduced device replacements and associated complications. Access Vascular's approach relies on intrinsic biomaterial properties rather than surface coatings or fillers. The devices target improved patient experience by reducing unnecessary needle sticks and treatment delays caused by device failure or replacement.

SEKISUI Diagnostics is a global leader in diagnostic reagents, biochemistry products, and point-of-care testing solutions with over 40 years of industry experience. The company manufactures and supplies clinical chemistry reagents, performing over 1.8 billion tests annually worldwide. Core product lines include Clinical Chemistry reagents for laboratory analyzers, Point-of-Care Testing (POCT) solutions in multiple formats to enable rapid diagnosis in office and clinic settings, and specialty biochemical enzymes for diagnostic reagent and biosensor manufacturers. SEKISUI also provides Blood Collection Tube Raw Materials and pre-analytic systems for plasma collection tubes, serving blood collection manufacturers globally. The Metrix® COVID/Flu Test represents their molecular diagnostics portfolio, offering point-of-care detection and differentiation of SARS-CoV-2, Flu A, and Flu B with small footprint and streamlined workflow. Beyond products, SEKISUI offers Biopharma Services supporting biotherapeutic and pharmaceutical manufacturing, technical transfer, and process scale-up. The company serves core laboratories, healthcare providers, in vitro diagnostics manufacturers, and distributors. SEKISUI combines analytical accuracy with operational efficiency, positioning products for cost containment and outcome improvement across clinical settings. The organization emphasizes patient-centric diagnostic solutions and maintains comprehensive technical and educational support for laboratory and clinical professionals.